Patient demographics and medical history
glioblastoma, ovarian cancer, cancer
GLIOBLASTOMA, OVARIAN CANCER, CANCER, FAP
Twenty-three patients were enrolled at six study sites in Switzerland. There were 11 patients in the ovarian cancer cohort and 12 in the glioblastoma cohort, of whom eight (72.7%) and eight (66.7%), respectively, were included in the EEP. Nine patients in each cohort (81.8% and 75%, respectively) completed the follow-up period. The mean age of the FAP was 61.9 years, and all patients were Caucasian. A summary of the diagnosis and extent of cancer at screening for the FAP is shown in Table 
Summary of diagnosis and extent of cancer at screening (full analysis population)The mean (± SD) extent of exposure to lisavanbulin in the safety population was 84.1 (± 119.1) days. The mean exposure was similar in both cohorts (81.6 days vs. 86.5 days in the ovarian cancer and glioblastoma cohorts, respectively).Six patients with ovarian cancer and one patient with glioblastoma had at least one dose adjustment. The mean (± SD) overall treatment compliance in the safety population was 98.3% (± 4.6), range 80.3–102.9%. This was similar across both cohorts (98.7% and 97.9% in the ovarian cancer and glioblastoma cohorts, respectively).